BioCentury
ARTICLE | Company News

Helsinn, Eisai sales and marketing update

December 7, 2015 8:00 AM UTC

Helsinn and Eisai said the American Society of Clinical Oncology (ASCO) has recognized Akynzeo netupitant/palonosetron as an option to prevent acute and delayed nausea and vomiting in patients recei...